The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

By D. Black, S. Greenspan, K. Ensrud, L. Palermo, J. McGowan, T. Lang, P. Garnero, M. Bouxsein, J. Bilezikian, C. Rosen. New England Journal of Medicine, 2003

1,114 citations recorded by the source corpus.

Subfields: Nephrology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/7ce0a3b951f2e05a0f72235d145e60648df91a68

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. (2008, methodology): “Nevertheless, in the PaTH study significant treatment effects on cortical BMD of the femoral neck (124,125) have been shown.”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “were disappointing [266], combination of teriparatide and denosumab generated greater increments in BMD and calculated bone strength compared to either drug alone [267],”
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “Several clinical studies [109, 110] have shown that prior or concurrent treatment with alendronate appears to interfere with the anabolic response to parathyroid hormone (PTH).”
Biology of RANK, RANKL, and osteoprotegerin (2007, background): “However, OPG in this latter setting does not appear to protect the skeleton against the increased bone resorption of secondary hyperparathyroidism mediated by PTH in patients with renal osteodystrophy or against vascular calcification.”
Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. (2007, background): “Use of imaging in epidemiologic studies has been an effective way to understand subclinical disease, particularly in the fields of osteoporosis (15), atherosclerosis (16), brain structure (17), and body composition (18).”
Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, result): “This is in contrast to clinical studies with alendronate and PTH, which show limited additive effects with this combination [147].”